Shilpak Chatterjee - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Shilpak Chatterjee

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Cell Metabolism|November 14, 2017

CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseShilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.

Nature Communications|January 20, 2022

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19Yogiraj Ray, Shekhar Ranjan Paul, Purbita Bandopadhyay, et al.

The Lancet Regional Health. Southeast Asia|February 13, 2026

Burden of MASLD and liver fibrosis: evidence from Phenome India cohortMeghana Arvind, Anshul Verma, Sreeshma Raj K, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Cell Metabolism|November 14, 2017

CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseShilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.

Nature Communications|January 20, 2022

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19Yogiraj Ray, Shekhar Ranjan Paul, Purbita Bandopadhyay, et al.

The Lancet Regional Health. Southeast Asia|February 13, 2026

Burden of MASLD and liver fibrosis: evidence from Phenome India cohortMeghana Arvind, Anshul Verma, Sreeshma Raj K, et al.

Pageof 5